Publications Database

Bostic J. Q. , King B. H. (2005)

Autism spectrum disorders: emerging pharmacotherapy.

Expert Opinion on Emerging Drugs

10(3), pp. 521-536.

Read Abstract (New Window)

Brkanac Z. , Raskind W. H. , King B. H. (2008)

Pharmacology and genetics of autism: implications for diagnosis and treatment.

Personalized Medicine

5(6), pp. 599-607

Read Abstract (New Window) Read Full (New Window)

Carr T. et al. (2016)

The relationship between treatment attendance, adherence, and outcome in a caregiver-mediated intervention for low-resourced families of young children with autism spectrum disorder.

Autism

August, 20(6), pp.:643-652.

Read Abstract (New Window)

Davazno P. , King B. H. (1996)

Open trial lamotrigine in the treatment of self-injurious behavior in an adolescent with profound mental retardation.

Journal of Child and Adolescent Psychopharmacology

6(4), pp. 273-279

Read Abstract (New Window)

Erickson C. A. et al. (2014)

STX209 (Arbaclofen) for autism spectrum disorders: An 8-week open-label study.

Journal of Autism and Developmental Disorders

44(4), pp. 958-964.

Read Abstract (New Window)

Howes O. D. et al.

Autism spectrum disorder: Consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology.

Journal of Psychopharmacology

Read Abstract (New Window)

Kasari C. L. et al. (2014)

Caregiver-mediated intervention for low-resourced preschoolers with autism: An RCT.

Pediatrics

July, 134(1), pp. e72-e79.

Read Abstract (New Window)

Kasari C. L. et al. (2016)

Children with autism spectrum disorder and social skills groups at school: a randomized trial comparing intervention approach and peer composition.

Journal of Child Psychology and Psychiatry

February, 57(2), pp. 171-179.

Read Abstract (New Window)

King B. H. , Bostic J. Q. (2006)

An update on pharmacologic treatments for autism spectrum disorders.

Child and Adolescent Psychiatric Clinics of North America

15(1), pp.161-175

Read Abstract (New Window)

King B. H. et al. (2013)

Baseline factors predicting placebo response to treatment in children and adolescents with autism spectrum disorders: A multisite randomized clinical trial.

JAMA Pediatrics

November, 167(11),

Read Abstract (New Window)

King B. H. et al. (2001)

Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder.

Journal of the American Academy of Child and Adolescent Psychiatry

40(6), pp. 658-665

Read Abstract (New Window)

King B. H. et al. (2009)

Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism.

Archives of General Psychiatry

66(6), pp. 583-590

Read Abstract (New Window)

King B. H. (2000)

Pharmacological treatment of mood disturbances, aggression and self-injury in persons with pervasive developmental disorders.

Journal of Autism and Developmental Disorders

30(5), pp. 439-445

Read Abstract (New Window)

Lecavalier L. et al. (2014)

Measuring anxiety as a treatment endpoint in youth with autism spectrum disorder.

Journal of Autism and Developmental Disorders

May, 44(5), pp. 1128-1143.

Read Abstract (New Window) Read Full (New Window)

Toth K. , King B. H. (2008)

Asperger's syndrome: Diagnosis and treatment

American Journal of Psychiatry

165(8), pp. 958-963

Read Extract (New Window)

Veenstra-VanderWeele J. et al.

Arbaclofen in children and adolescents with autism spectrum disorder: A randomized, controlled, phase 2 trial.

Neuropsychopharmacology

Read Abstract (New Window)

Volkmar F. R. et al. (2014)

Practice parameter for the assessment and treatment of children and adolescents with autism spectrum disorder.

Journal of the American Academy of Child and Adolescent Psychiatry

53(2), pp. 237-257.

Read Abstract (New Window) Read Full (New Window)